Multiple Non-Small Cell Lung Cancer-associated tumor antigens (NSCLC TAAs)

Multiple Non-Small Cell Lung Cancer (NSCLC)-associated tumor antigens refer to a heterogeneous group of proteins that are overexpressed or aberrantly expressed in lung cancer cells, serving as targets for immunotherapy. This collective target includes cancer-testis antigens (e.g., MAGE-A2, MAGE-A3, NY-ESO-1), oncofetal antigens (e.g., Carcinoembryonic Antigen/CEA), and overexpressed self-antigens (e.g., HER2/neu, P53, and Survivin) (Zarogoulidis et al., 2013, Journal of Thoracic Disease). In clinical development, these antigens are often targeted simultaneously using multi-epitope vaccines like OSE-2101 (Tedopi) to overcome the high degree of intratumoral heterogeneity and prevent immune escape (Felip et al., 2021, Annals of Oncology). The biological functions of these individual antigens vary, involving roles in cell cycle progression, apoptosis inhibition, and signal transduction, which contribute to the malignant phenotype of NSCLC. By stimulating a broad CD8+ cytotoxic T-cell response against multiple epitopes, these therapies aim to provide a more robust and durable anti-tumor effect than single-antigen approaches. However, the efficacy of targeting these antigens is often restricted to specific patient populations, such as those who are HLA-A2 positive, and requires careful monitoring for immune-related side effects (OSE Immunotherapeutics, 2023).

Other names

NSCLC tumor-associated antigensLung cancer antigensMulti-antigen NSCLC vaccine targetsPolyvalent NSCLC antigens

Induction of a poly-epitope specific cytotoxic T-lymphocyte (CTL) response by priming the immune system to recognize multiple tumor-specific proteins simultaneously.